ATE362379T1 - Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv) - Google Patents
Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv)Info
- Publication number
- ATE362379T1 ATE362379T1 AT97954878T AT97954878T ATE362379T1 AT E362379 T1 ATE362379 T1 AT E362379T1 AT 97954878 T AT97954878 T AT 97954878T AT 97954878 T AT97954878 T AT 97954878T AT E362379 T1 ATE362379 T1 AT E362379T1
- Authority
- AT
- Austria
- Prior art keywords
- rev
- immunodeficiency virus
- tat
- cells
- hiv
- Prior art date
Links
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 title abstract 4
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 241000725303 Human immunodeficiency virus Species 0.000 title 2
- 230000006698 induction Effects 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 206010061598 Immunodeficiency Diseases 0.000 abstract 3
- 208000029462 Immunodeficiency disease Diseases 0.000 abstract 3
- 101710150344 Protein Rev Proteins 0.000 abstract 3
- 101710149951 Protein Tat Proteins 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 230000007813 immunodeficiency Effects 0.000 abstract 3
- 230000005867 T cell response Effects 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 230000002163 immunogen Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000004393 prognosis Methods 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
- C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
- C07K14/16—HIV-1 ; HIV-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
- C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- AIDS & HIV (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/733,789 US6024965A (en) | 1996-10-18 | 1996-10-18 | Induction of REV and TAT specific cytotoxic T-cells for prevention and treatment of human immunodeficiency virus (HIV) infection |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE362379T1 true ATE362379T1 (de) | 2007-06-15 |
Family
ID=24949122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT97954878T ATE362379T1 (de) | 1996-10-18 | 1997-10-17 | Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv) |
Country Status (10)
Country | Link |
---|---|
US (3) | US6024965A (de) |
EP (1) | EP0930894B1 (de) |
JP (2) | JP2001504812A (de) |
KR (1) | KR20000052649A (de) |
AT (1) | ATE362379T1 (de) |
AU (1) | AU730887B2 (de) |
CA (1) | CA2268720A1 (de) |
DE (1) | DE69737736D1 (de) |
NZ (1) | NZ335612A (de) |
WO (1) | WO1998017309A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5891994A (en) * | 1997-07-11 | 1999-04-06 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
IT1297090B1 (it) | 1997-12-01 | 1999-08-03 | Barbara Ensoli | Tat di hiv-1 o suoi derivati, da soli od in combinazione, a scopo vaccinale, profilattico e terapeutico, contro l'aids i tumori e le |
US20010019714A1 (en) * | 1998-04-07 | 2001-09-06 | Charles D. Y. Sia | Hiv-specific cytotoxic t-cell responses |
US7105164B1 (en) * | 1998-04-07 | 2006-09-12 | Sanofi Pasteur Limited | HIV-specific cytotoxic T-cell responses |
US20010008627A1 (en) * | 1999-01-22 | 2001-07-19 | Soll David R. | Hiv-encoded chemoattractant |
MXPA01011499A (es) | 1999-05-13 | 2002-06-04 | American Cyanamid Co | Formulaciones de combinacion de adyuvantes. |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
JP2003510094A (ja) | 1999-09-08 | 2003-03-18 | トランジェーヌ、ソシエテ、アノニム | Muc−1由来のペプチド |
US6399067B1 (en) * | 2000-04-28 | 2002-06-04 | Thymon L.L.C. | Methods and compositions for impairing multiplication of HIV-1 |
US20080044435A1 (en) * | 2004-03-16 | 2008-02-21 | Cohen David I | Tat-Based Tolerogen Compositions and Methods of Making and Using Same |
DE10053781B4 (de) | 2000-10-30 | 2008-07-03 | Geneart Ag | Kernexportreportersystem |
US20020107193A1 (en) * | 2000-11-09 | 2002-08-08 | Glazner Gordon W. | Therapeutic uses for IP3 receptor-mediated calcium channel modulators |
AU2002225972B2 (en) * | 2000-11-10 | 2006-06-29 | Wyeth Holdings Corporation | Adjuvant combination formulations |
GB0323840D0 (en) * | 2003-10-10 | 2003-11-12 | Ist Superiore Sanita | Vaccines |
US20050208482A1 (en) * | 2004-03-16 | 2005-09-22 | Cohen David I | Tat-based immunomodulatory compositions and methods for their discovery and use |
WO2006088740A2 (en) | 2005-02-15 | 2006-08-24 | Thymon, L.L.C. | Methods and compositions for impairing multiplication of hiv-1 |
US7455249B2 (en) * | 2006-03-28 | 2008-11-25 | Illinois Tool Works Inc. | Combined direct and indirect charging system for electrostatically-aided coating system |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
BRPI1009215B1 (pt) | 2009-03-23 | 2019-10-29 | Nanirx Inc | composição farmacêutica compreendendo uma sequência de aminoácidos modificada da proteína trans-ativadora de transcrição (tat) do vírus da imunodeficiência humana (hiv) e uso de um polipeptídeo derivado de tat para tratar câncer |
GB201004656D0 (en) * | 2010-03-19 | 2010-05-05 | Ensoli Barbara | Immune therapy |
EP2550362B1 (de) | 2010-03-25 | 2017-01-04 | Oregon Health&Science University | Cmv-glycoproteine und rekombinante vektoren |
US8486717B2 (en) | 2011-01-18 | 2013-07-16 | Symbolics, Llc | Lateral flow assays using two dimensional features |
CA2832109C (en) | 2011-06-10 | 2021-07-06 | Oregon Health & Science University | Cmv glycoproteins and recombinant vectors |
AU2012216792A1 (en) | 2011-09-12 | 2013-03-28 | International Aids Vaccine Initiative | Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies |
US9402894B2 (en) | 2011-10-27 | 2016-08-02 | International Aids Vaccine Initiative | Viral particles derived from an enveloped virus |
EP2679596B1 (de) | 2012-06-27 | 2017-04-12 | International Aids Vaccine Initiative | HIV-1 Env-proteinvariante |
US20150065381A1 (en) | 2013-09-05 | 2015-03-05 | International Aids Vaccine Initiative | Methods of identifying novel hiv-1 immunogens |
US9663556B2 (en) | 2013-10-04 | 2017-05-30 | Pin Pharma, Inc. | Treatment of cancers with immunostimulatory HIV tat derivative polypeptides |
EP2873423B1 (de) | 2013-10-07 | 2017-05-31 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3069730A3 (de) | 2015-03-20 | 2017-03-15 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
EP3072901A1 (de) | 2015-03-23 | 2016-09-28 | International Aids Vaccine Initiative | Lösliche hiv-1-hüllglykoproteintrimere |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8923123D0 (en) * | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
US5336758A (en) * | 1990-03-09 | 1994-08-09 | The United States Of America As Represented By The Department Of Health And Human Services | Peptides stimulating cytotoxic T cells immune to HIV RT |
WO1994015634A1 (en) * | 1992-12-30 | 1994-07-21 | Matthias Rath | Tat and rev oligopeptides in hiv treatment |
-
1996
- 1996-10-18 US US08/733,789 patent/US6024965A/en not_active Expired - Fee Related
-
1997
- 1997-10-17 AT AT97954878T patent/ATE362379T1/de not_active IP Right Cessation
- 1997-10-17 KR KR1019990703421A patent/KR20000052649A/ko not_active Application Discontinuation
- 1997-10-17 EP EP97954878A patent/EP0930894B1/de not_active Expired - Lifetime
- 1997-10-17 DE DE69737736T patent/DE69737736D1/de not_active Expired - Lifetime
- 1997-10-17 JP JP51868698A patent/JP2001504812A/ja active Pending
- 1997-10-17 WO PCT/IB1997/001402 patent/WO1998017309A1/en active IP Right Grant
- 1997-10-17 AU AU47195/97A patent/AU730887B2/en not_active Ceased
- 1997-10-17 NZ NZ335612A patent/NZ335612A/xx not_active IP Right Cessation
- 1997-10-17 US US09/284,651 patent/US6319666B1/en not_active Expired - Lifetime
- 1997-10-17 CA CA002268720A patent/CA2268720A1/en not_active Abandoned
- 1997-12-22 US US08/995,916 patent/US5942401A/en not_active Expired - Fee Related
-
2006
- 2006-03-30 JP JP2006093367A patent/JP2006265255A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU4719597A (en) | 1998-05-15 |
JP2006265255A (ja) | 2006-10-05 |
KR20000052649A (ko) | 2000-08-25 |
AU730887B2 (en) | 2001-03-15 |
WO1998017309A1 (en) | 1998-04-30 |
US5942401A (en) | 1999-08-24 |
US6319666B1 (en) | 2001-11-20 |
CA2268720A1 (en) | 1998-04-30 |
NZ335612A (en) | 2000-10-27 |
DE69737736D1 (de) | 2007-06-28 |
EP0930894A1 (de) | 1999-07-28 |
EP0930894B1 (de) | 2007-05-16 |
JP2001504812A (ja) | 2001-04-10 |
US6024965A (en) | 2000-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69737736D1 (de) | Induktion rev- und tat-spezifischer zytotoxischer t-zellen zur prävention und behandlung einer infektion durch humanen immundefizienz-virus (hiv) | |
Belshe et al. | Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection | |
Nara et al. | Persistent infection of chimpanzees with human immunodeficiency virus: serological responses and properties of reisolated viruses | |
Krowka et al. | Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. | |
DE69535757D1 (de) | Rekombinanter immunschwächepoxvirus | |
ES2009350A6 (es) | Procedimiento para la preparacion de vectores de expresion que codifican una nueva proteina. | |
DK33190A (da) | Hiv-3 retrovirus og anvendelse heraf | |
ES8705522A1 (es) | Un procedimiento para la preparacion de derivados purificados de una glicoproteina. | |
ATE418562T1 (de) | Ctl epitope des epstein-barr virus | |
ZA200107072B (en) | HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV. | |
NO863803L (no) | Vaksiner og immunoanalyser for ervervet immunsviktsyndrom (aids). | |
BR0114036A (pt) | Peptìdeos de hiv, antìgenos, composições de vacina, kit de imunoensaio e um método para detectar anticorpos induzidos pelo hiv | |
DE60023300D1 (de) | Verwendung von cpg als adjuvans für hivimpstoff | |
HUP0202502A2 (hu) | Virális fertőzőképességet blokkoló peptidek és eljárások ezek alkalmazására | |
Shugars et al. | Secretory leukocyte protease inhibitor blocks infectivity of primary monocytes and mononuclear cells with both monocytotropic and lymphocytotropic strains of human immunodeficiency virus type 1 | |
HUP0303132A2 (hu) | Szabályozó és kiegészítő HIV-peptidek, antigének, vakcinakészítmények, immunológiai mérési reagenskészletek és HIV által indukált antitestek detektálására szolgáló eljárás | |
HUP0105070A2 (hu) | Hepatitis B vírus fertőzések megelőzésére és kezelésére szolgáló készlet | |
DK76688D0 (da) | Vaccine indeholdende f-proteinet fra aids-virus | |
FR2868318B1 (fr) | Antigene tat stabilise et ses applications pour la vaccination anti-vih | |
DE60024259D1 (de) | Trennung eines humanen retrovirus | |
ATE284709T1 (de) | Virale chimären aus caev und hiv-1 genetischen elementen | |
KR920700698A (ko) | 아메리카 자리콩 항바이러스성 단백질-모노클로날항체 결합체 | |
EA199700353A1 (ru) | Композиция и способ для определения приобретенного синдрома иммунодефицита, способ приготовления названной композиции | |
RU2006118106A (ru) | Вектор химерного аденовируса типа 5/типа 35 | |
WO2001070941A3 (en) | An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |